A pharmaceutical care program to improve adherence to statin therapy: A randomized controlled trial

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 1905-1913

  Eussen, Simone R B M ^a   Van Der Elst, Menno E ^b   Klungel, Olaf H ^a   Rompelberg, Cathy J M ^c   Garssen, Johan ^a   Oosterveld, Marco H ^d   De Boer, Anthonius ^a   De Gier, Johan J ^e   Bouvy, Marcel L ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Waldeck Service Apotheek   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adherence; Cardiovascular drugs; Lipids; Pharmaceutical care

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEALTH PROGRAM; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACIST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC;

EID: 78649963973     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P281     Document Type: Article

References (43)

1. Colivicc F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7. DOI 10.1161/STROKEAHA.107.487017
2. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21:485-8.
3. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
4. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005;61:667-74. DOI 10.1007/s00228-005-0980-z
5. Council of Europe, Committee of Ministers. Resolution ResAP(2001)2 concerning the pharmacist's role in the framework of health security. https://wcd.coe.int/ViewDoc.jsp?id = 193721&BackColorInternet = 9999CC&BackColorIntranet = FFBB55&BackColorLogged = FFAC75 2001 (accessed 2009 Nov 12).
6. World Health Organization (WHO). The role of the pharmacist in the health care system. http://apps.who.int/medicinedocs/es/d/Jh2995e/1.9.html 1994 (accessed 2009 Nov 12).
7. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
8. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20:1508-16.
9. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-6.
10. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71. DOI 10.1001/jama.296.21.joc60162
11. Nietert PJ, Tilley BC, Zhao W, et al. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009;47:32-40. DOI 10.1097/MLR.0b013e3181808c17
12. Nola KM, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000;40:166-73.
13. Paulós CP, Nygren CE, Celedón C, Cárcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother 2005;39:939-43. DOI 10.1345/aph.1E347
14. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcomes of lipidlowering drug therapy. J Clin Pharm Ther 2004;29:23-30.
15. Poston J, Loh E, Dunham W. The medication use study. Can Pharm J 1998;131:31-8.
16. Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW Jr. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 2006;43:1205-10. DOI 10.1016/j.jvs2006.02.019
17. Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006;15:115-21. DOI 10.1002/pds.1198 (Pubitemid 43316254)
18. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22(suppl 3):13-23.
19. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008;33:17-23. DOI 10.1111/j.1365-2710.2008.00878.x
20. Ministerie van Volksgezondheid, Welzijn en Sport. Wijziging Regeling farmaceutische hulp 1996. Dutch. https://zoek.officielebekendmakingen.nl/stcrt- 1999-140-p7-SC19840.html (accessed 2010 Jul 26).
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007;18:1311-7. DOI 10.1007/s00198-007-0410- 4
23. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006;59:11-7. DOI 10.1016/j.jclinepi.2005.05.005
24. Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 2010;63:422-7. DOI 10.1016/j.jclinepi.2009.07.001
25. Herings RMC, Leufkens HGM, Heerdink ER, Klungel OH, Breekveldt- Postma NP. Chronic pharmacotherapy forever. PHARMO report 2002. http://www.pharmo.nl/ pdf/reports/Chronic%20Pharmacotherapy%20Forever.pdf (accessed 2009 Oct 19).
26. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2010. http://www.whocc.no/filearchive/publications/2010guidelines.pdf (accessed 2009 Oct 19).
27. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-9. DOI 10.1093/eurheartj/ehl391
28. Thomas S, Van der Weijden T, Van Drenth BB, Haverkort AFM, Hooi JD, Van der Laan JD. NHG-Standaard Cholesterol. Dutch. Huisarts Wet 1999;42:406-17.
29. Dutch Institute for Healthcare Improvement CBO. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterol-concentratie. Dutch. Consensus Cholesterol tweede herziening, 1998.
30. McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007;41:1805-11. DOI 10.1345/aph.1K209
31. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003;9:404-11.
32. Hamann GF, Weimar C, Glahn J, Busse O, Diener HC. Adherence to secondary stroke prevention strategies - results from the German Stroke Data Bank. Cerebrovasc Dis 2003;15:282-8. DOI 10.1159/000069490 (Pubitemid 36438733)
33. White IR. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005;14:327-47.
34. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-26. DOI 10.1046/j.1524-4733.2000.36006.x
35. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:1639-46. DOI 10.1016/j.clinthera.2005.10.005
36. Poluzzi E, Strahinja P, Lanzoni M, et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008;64:425-32. DOI 10.1007/s00228-007-0428-8
37. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005;22:163-71.
38. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007;21:311-6.
39. Schwed A, Fallab CL, Burnier M, et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999;39:402-9. (Pubitemid 29159830)
40. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-43. DOI 10.1002/pds.1341
41. Hewitt CE, Torgerson DJ, Miles JN. Individual allocation had an advantage over cluster randomization in statistical efficiency in some circumstances. J Clin Epidemiol 2008;61:1004-8. DOI 10.1016/j.jclinepi.2007.12.002
42. Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ 2001;322:355-7.
43. Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ 2003;327:785-9. DOI 10.1136/bmj.327.7418.785